- Americans pay several times as much for insulin as people in other developed countries.
- Eli Lilly has drastically cut the list price of some of its insulin products, putting pharmacy-benefit managers in a bind.
- The move effectively puts PBMs in a bind, likely forcing them to give up some of the rebates for those products.
- The move could be a mortal blow if other pharma companies follow suit.
- House Republicans launched an investigation into PBMs, suggesting the political focus is shifting to the middlemen.
Eli Lilly’s Insulin Decision Puts Others in Hot Seat
Drugmaker’s plan moves the spotlight to industry middlemen, who face a barrage of investigations
David Wainer
